EX9 Overzicht aandelen Exelixis, Inc., een oncologiebedrijf, richt zich op het ontdekken, ontwikkelen en commercialiseren van nieuwe medicijnen voor moeilijk te behandelen kankers in de Verenigde Staten. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
Exelixis, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Exelixis Historische aandelenkoersen Huidige aandelenkoers US$31.55 52 Week Hoogtepunt US$36.13 52 Week Laag US$18.26 Bèta 0.53 1 maand verandering -3.31% 3 maanden verandering -7.29% 1 Jaar Verandering 68.36% 3 jaar verandering 86.91% 5 jaar verandering 67.57% Verandering sinds IPO 62.63%
Recent nieuws en updates
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07 Meer updates bekijken
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07
Investor sentiment improves as stock rises 23% Nov 07 Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024
Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 16 Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Independent Director recently sold €831k worth of stock Aug 14
Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Aug 08
Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.25 in 2Q 2023) Aug 07 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.
Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Aug 06
Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 24
Independent Director recently sold €531k worth of stock May 24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 22
First quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 1Q 2023) May 01
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024 May 01
Exelixis, Inc., Annual General Meeting, May 30, 2024 Apr 20
Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 17
Executive Vice President of Commercial recently sold €932k worth of stock Mar 03
Full year 2023 earnings released: EPS: US$0.65 (vs US$0.57 in FY 2022) Feb 07
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024 Feb 07
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Jan 25 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Jan 24
Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares. Jan 09 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.
Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Dec 04
Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Nov 11
Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022) Nov 02
Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Oct 23
Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Aug 25 Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Aug 04
Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 21
Exelixis, Inc. Elects Dave Johnson to its Board of Directors Jun 01
First quarter 2023 earnings released: EPS: US$0.12 (vs US$0.21 in 1Q 2022) May 10
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 May 10
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors May 08 Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma Feb 15
Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Feb 14
Full year 2022 earnings released: EPS: US$0.57 (vs US$0.73 in FY 2021) Feb 08
Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023 Feb 08
Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Jan 10
Exelixis, Inc. Provides Revenue Guidance for Full Year 2023 Jan 09 Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Dec 23
Exelixis, Inc. Announces Board Appointments Dec 17
Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Dec 10
Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Dec 09
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.23 (vs US$0.12 in 3Q 2021) Nov 03
Exelixis, Inc. Provides Revenue Guidance for 2022 Nov 02
Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022 Oct 27
Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 Sep 11
Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 Sep 08
Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021) Aug 11
Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022 Aug 10
Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint Jul 12
Investor sentiment improved over the past week Jun 25
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer Jun 22
Executive Vice President of Commercial recently sold €320k worth of stock Jun 04
Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients May 27
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021) May 11
Insufficient new directors Apr 27 Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors Apr 14
Co-Founder & Independent Chairman recently sold €1.5m worth of stock Mar 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 18
Exelixis, Inc. Provides Earnings Guidance for the Year 2022 Feb 18
Bristol Myers Squibb and Exelixis, Inc. Announces Two-Year Follow-Up Results from Analyses of the Phase 3 CheckMate -9ER Trial Feb 15
Exelixis, Inc. Provides Sales Guidance for the Year 2022 Feb 11
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 Jan 19
Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021; Revenue Guidance for the Full Year 2022 Jan 10 Rendement voor aandeelhouders EX9 DE Biotechs DE Markt 7D -1.9% 1.2% 2.3% 1Y 68.4% -5.6% 16.7%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: EX9 overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -5.6 % opleverde.
Rendement versus markt: EX9 overtrof de German markt, die het afgelopen jaar een rendement opleverde van 16.7 %.
Prijsvolatiliteit Is EX9's price volatile compared to industry and market? EX9 volatility EX9 Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stabiele aandelenkoers: De aandelenkoers van EX9 is de afgelopen 3 maanden volatiel geweest in vergelijking met de German markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van EX9 in het afgelopen jaar te bepalen.
Over het bedrijf Exelixis, Inc., een oncologiebedrijf, richt zich op het ontdekken, ontwikkelen en op de markt brengen van nieuwe geneesmiddelen voor moeilijk te behandelen kankers in de Verenigde Staten. Het bedrijf biedt CABOMETYX-tabletten aan voor de behandeling van patiënten met gevorderd niercelcarcinoom die een voorafgaande anti-angiogene therapie hebben ondergaan, en COMETRIQ-capsules voor de behandeling van progressieve en metastatische medullaire schildklierkanker. CABOMETYX en COMETRIQ zijn afgeleid van cabozantinib, een remmer van meerdere tyrosinekinasen, waaronder MET-, AXL-, RET- en VEGF-receptoren.
Meer tonen Exelixis, Inc. Samenvatting Hoe verhouden de winst en inkomsten van Exelixis zich tot de beurswaarde? EX9 fundamentele statistieken Marktkapitalisatie €9.28b Inkomsten(TTM ) €453.15m Inkomsten(TTM ) €2.02b
20.5x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) EX9 resultatenrekening (TTM ) Inkomsten US$2.08b Kosten van inkomsten US$78.00m Brutowinst US$2.00b Overige uitgaven US$1.54b Inkomsten US$466.92m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
Feb 11, 2025
Winst per aandeel (EPS) 1.64 Brutomarge 96.25% Nettowinstmarge 22.43% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde EX9 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/11 07:26 Aandelenkoers aan het einde van de dag 2025/02/05 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten Exelixis, Inc. wordt gevolgd door 41 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Ishan Majumdar Baptista Research Peter Lawson Barclays George Farmer BMO Capital Markets Equity Research
Toon 38 meer analisten 
